D05 Stock Overview A biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Deciphera Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Deciphera Pharmaceuticals Historical stock prices Current Share Price US$23.60 52 Week High US$23.80 52 Week Low US$9.51 Beta 0.18 1 Month Change 0% 3 Month Change 60.49% 1 Year Change 84.66% 3 Year Change -19.18% 5 Year Change 11.58% Change since IPO 40.22%
Recent News & Updates
Deciphera Pharmaceuticals, Inc. Files Form 15 Jun 22 Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index
Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (Tgct) At the 2024 Asco Annual Meeting and Online Publication in the Lancet Jun 05
First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023) May 11 Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion. Apr 30
Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024 Apr 27 See more updates
Deciphera Pharmaceuticals, Inc. Files Form 15 Jun 22 Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index
Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (Tgct) At the 2024 Asco Annual Meeting and Online Publication in the Lancet Jun 05
First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023) May 11 Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion. Apr 30
Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024 Apr 27
Full year 2023 earnings released: US$2.29 loss per share (vs US$2.37 loss in FY 2022) Feb 07
Deciphera Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 06, 2024 Feb 02
Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 Jan 09
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 Jan 05
President recently sold €437k worth of stock Dec 17
Senior VP & Chief Commercial Officer recently sold €205k worth of stock Dec 04
President recently sold €244k worth of stock Nov 02
President recently sold €244k worth of stock Nov 02
Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor Oct 31
Third quarter 2023 earnings released: US$0.58 loss per share (vs US$0.55 loss in 3Q 2022) Oct 31
New minor risk - Share price stability Oct 10
Second quarter 2023 earnings released: US$0.57 loss per share (vs US$0.60 loss in 2Q 2022) Aug 10
Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023 Aug 05
Deciphera Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 03
Now 22% undervalued after recent price drop Jun 15
Deciphera Pharmaceuticals, Inc. to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-In-Progress Poster for Insights Pivotal Phase 3 Study of QINlock (Rpretinib) at the 2023 American Society of Clinical Oncology Annual Meeting May 26
Now 22% undervalued after recent price drop May 23
Independent Director recently bought €139k worth of stock May 15
First quarter 2023 earnings released: US$0.60 loss per share (vs US$0.80 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$2.37 loss per share (vs US$5.16 loss in FY 2021) Feb 08
Deciphera Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 07, 2023 Feb 01
Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session Jan 25
Now 21% undervalued Jan 11
Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022 Jan 05 Deciphera Pharmaceuticals, Inc. Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.37 loss in 3Q 2021) Nov 04
Deciphera Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022 Sep 12
Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022 Sep 11
Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Study Results in Journal of Clinical Oncology Aug 11
Second quarter 2022 earnings released: US$0.60 loss per share (vs US$1.22 loss in 2Q 2021) Aug 05
Deciphera Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Senior Vice President and Chief Business Officer Jun 17
First quarter 2022 earnings released: US$0.80 loss per share (vs US$1.06 loss in 1Q 2021) May 05
Deciphera Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022 May 03
Insufficient new directors Apr 27
Deciphera Pharmaceuticals, Inc Presents Preclinical Data from DCC-3116 Program At the AACR Annual Meeting Apr 13
Insufficient new directors Mar 02
Deciphera Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 08, 2022 Feb 02
Deciphera Pharmaceuticals, Inc. Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session Jan 25
Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Dec 22
Deciphera Pharmaceuticals, Inc. Receives European Commission Approval of QINLOCK® for Treatment of Fourth-Line Gastrointestinal Stromal Tumor Nov 24
Third quarter 2021 earnings released: US$1.37 loss per share (vs US$1.13 loss in 3Q 2020) Nov 03
Executive VP & Chief Medical Officer recently sold €76k worth of stock Oct 09 Deciphera Pharmaceuticals, Inc. Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Second quarter 2021 earnings released: US$1.22 loss per share (vs US$1.20 loss in 2Q 2020) Aug 05
Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene Jul 01
Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Jun 05
First quarter 2021 earnings released: US$1.06 loss per share (vs US$1.36 loss in 1Q 2020) May 06
New 90-day low: €34.40 Feb 27
Full year 2020 earnings released: US$4.78 loss per share (vs US$4.49 loss in FY 2019) Feb 11
Revenue beats expectations Feb 11
Deciphera Pharmaceuticals, Inc. Announces Appointment of Margarida Duarte as Senior Vice President, Head of International Feb 10
Deciphera Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 09, 2021 Feb 03
New 90-day low: €38.20 Jan 23
New 90-day low: €43.00 Jan 07
Deciphera Pharmaceuticals, Inc. Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor Dec 01
New 90-day high: €54.50 Nov 13 Deciphera Pharmaceuticals, Inc. Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
Revenue beats expectations Nov 07
Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize Qinlock (Ripretinib) Nov 07
Specialised Therapeutics Asia Signs an Agreement with Deciphera Pharmaceuticals, Inc. to Commercialise the Switch-Control Tyrosine Kinase Inhibitor QINLOCK (ripretinib) Nov 06
Deciphera Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 29
New 90-day high: €52.50 Oct 24
New 90-day high: €48.20 Oct 08
Deciphera Pharmaceuticals, Inc. Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology Virtual Congress 2020 Sep 19
Deciphera Pharmaceuticals, Inc. Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 Sep 18
New 90-day low - €36.80 Aug 20
Deciphera Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 04, 2020 Jul 31
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from Russell Microcap Index Jul 02 Shareholder Returns D05 DE Biotechs DE Market 7D 1.7% -0.1% -0.2% 1Y 84.7% -4.6% 13.7%
See full shareholder returns
Return vs Market: D05 exceeded the German Market which returned 3.2% over the past year.
Price Volatility Is D05's price volatile compared to industry and market? D05 volatility D05 Average Weekly Movement 22.0% Biotechs Industry Average Movement 6.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.1% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: D05's share price has been volatile over the past 3 months.
Volatility Over Time: D05's weekly volatility has increased from 12% to 22% over the past year.
About the Company Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage.
Show more Deciphera Pharmaceuticals, Inc. Fundamentals Summary How do Deciphera Pharmaceuticals's earnings and revenue compare to its market cap? D05 fundamental statistics Market cap €2.06b Earnings (TTM ) -€177.33m Revenue (TTM ) €162.89m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) D05 income statement (TTM ) Revenue US$174.91m Cost of Revenue US$242.52m Gross Profit -US$67.61m Other Expenses US$122.80m Earnings -US$190.42m
Last Reported Earnings
Mar 31, 2024
Earnings per share (EPS) -2.20 Gross Margin -38.66% Net Profit Margin -108.87% Debt/Equity Ratio 0%
How did D05 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/06/11 21:09 End of Day Share Price 2024/06/11 00:00 Earnings 2024/03/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Deciphera Pharmaceuticals, Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Madhu Kumar B. Riley Securities, Inc. Arlinda Lee Canaccord Genuity Charles Duncan Cantor Fitzgerald & Co.
Show 14 more analysts 
